# TransMedics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transmedics

- Industry: Medical Devices & Equipment
- Headquarters: Andover, US
- Website: www.transmedics.com
- Total disclosed funding: $230M
- Latest round: Series F (May 12, 2016)
- Investors on record: 23

## About

TransMedics, Inc. is an innovative healthcare company focused on enhancing organ transplantation through advanced medical technologies, including its flagship Organ Care System (OCS™).Founded in 1998 and headquartered in Andover, US, TransMedics specializes in organ transplantation technologies. The company was founded by Waleed Hassanein, who has a background in medical technology innovation. TransMedics has raised a total of USD 130.00 mn through various funding rounds, with the latest round being a Venture Debt of USD 400.00 mn. The company has successfully completed 21 funding deals.TransMedics specializes in the development and provision of advanced medical technologies designed for organ transplantation, specifically through its flagship product, the Organ Care System (OCS™). This FDA-approved technology is utilized for lung, heart, and liver transplants, significantly enhancing the viability of donor organs through a unique method of normothermic perfusion. By eliminating the limitations associated with cold storage, the OCS™ system allows for better management of ischemic time and distance constraints, ultimately improving clinical outcomes for transplant patients. The OCS™ Heart, which caters to both Donation After Brain Death (DBD) and Donation After Circulatory Death (DCD) donors, exemplifies the company's commitment to innovation within the transplantation sector. TransMedics’ products primarily target transplant centers and hospitals within the United States, aiming to revolutionize the transplantation process and improve patient care.TransMedics generates revenue through the sale and lease of its OCS™ technology, along with accompanying clinical services tailored to maximize transplant efficiency and outcomes. For the year 2024, the company reported revenue of USD 441.54 mn and an EBITDA of USD 57.25 mn. Transactions typically involve direct sales or partnerships with hospitals and transplant centers that utilize the OCS™ systems for their transplantation procedures. The company's revenue model is heavily oriented toward B2B relationships, as it collaborates closely with healthcare providers to implement its solutions effectively, establishing a critical role in the organ transplantation ecosystem. The continuous growth of the National OCS™ Program further solidifies TransMedics’ position as an essential player in this specialized market.TransMedics plans to utilize its recent funding to accelerate growth through the development of new products and expansion into additional markets. The company is focused on designing new versions of its OCS™ technology to enhance organ preservation further. Plans are in place to expand its market reach, targeting regions beyond the United States by 2025. Following its successful IPO in May 2019, raising USD 91 mn, and subsequent offerings in 2020 and 2022, TransMedics aims to leverage these funds to support its strategic initiatives and enhance its operational capabilities.

## Funding rounds

- Series F, May 12, 2016, $51M — Flagship Pioneering, Kleiner Perkins, BioStar Capital, Abrams Capital, LLC, Pharmstandard International S.A., Ervington Investments, Inbio Ventures, Fayerweather Capital Partners, LLC
- Series F, May 29, 2015, $20M — Flagship Pioneering, Kleiner Perkins
- Series D, Nov 7, 2012, $36M — Flagship Pioneering, Kleiner Perkins, Hercules Capital, Abrams Capital, LLC
- Series B, Feb 17, 2010, $35M — Alta Partners, Flagship Pioneering, Kleiner Perkins, VantagePoint Capital, Foundation Capital, CB Health Ventures, Sherbrooke Capital, Tudor Investment Corporation, POSCO BioVentures, Sagamore Investments
- Series D, Apr 2, 2007, $23M — 3i, Alta Partners, Flagship Pioneering, VantagePoint Capital, CB Health Ventures, Sherbrooke Capital, Tudor Investment Corporation, POSCO BioVentures, Sagamore Investments
- Series C, Nov 23, 2005, $30M — 3i, Alta Partners, Flagship Pioneering, VantagePoint Capital, CB Health Ventures, Sherbrooke Capital, POSCO BioVentures, Sagamore Investments
- Series C, Aug 3, 2005, $0.3M — Alta Partners, VantagePoint Capital, CB Health Ventures, Panorama Capital, Sherbrooke Capital, POSCO BioVentures
- Series B, Dec 22, 2003, $26M — 3i, Alta Partners, Flagship Pioneering, CB Health Ventures, CDPQ, Sherbrooke Capital, POSCO BioVentures, Novel Bioventures
- Series B, Sep 4, 2001, $8.3M — Alta Partners, CDPQ, Chase Equity Partners, MedEquity Capital

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C, Series D
- CDPQ — Series B
- Chase Equity Partners — Series B
- MedEquity Capital (https://capitalatlas.ai/funds/medequity-capital) — Series B
- 3i (https://capitalatlas.ai/funds/3i) — Series B, Series C, Series D
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B, Series C, Series D, Series F
- CB Health Ventures (https://capitalatlas.ai/funds/cb-health-ventures) — Series B, Series C, Series D
- Sherbrooke Capital (https://capitalatlas.ai/funds/sherbrooke-capital) — Series B, Series C, Series D
- POSCO BioVentures (https://capitalatlas.ai/funds/posco-bioventures) — Series B, Series C, Series D
- Novel Bioventures — Series B
- VantagePoint Capital (https://capitalatlas.ai/funds/vantagepoint-capital) — Series C, Series D, Series B
- Panorama Capital — Series C
- Sagamore Investments — Series C, Series D, Series B
- Tudor Investment Corporation — Series D, Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series D, Series F
- Foundation Capital (https://capitalatlas.ai/funds/foundation-capital) — Series B
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series D
- Abrams Capital, LLC — Series D, Series F
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series F
- Pharmstandard International S.A. — Series F
- Ervington Investments (https://capitalatlas.ai/funds/ervington-investments) — Series F
- Inbio Ventures — Series F
- Fayerweather Capital Partners, LLC — Series F